Group items tagged

"From the perspective of the USTR, the TPP is not a threat to global health initiatives that rely on generics, but rather a blueprint for international norms that promote innovation in global health and elsewhere. However, amfAR's Senior Research Advisor, Brian Honermann, labels the USTR's outlook on HIV and the TPP as "inaccurate." He notes that the TPP contains "unprecedented intellectual property protections" around data exclusivity and the scope of patentability, both of which could make it harder to integrate new treatment options into large public sector programs that rely overwhelmingly on off-label drugs. "